The Medicines (MDCO) Earning Somewhat Positive Press Coverage, Analysis Finds

Press coverage about The Medicines (NASDAQ:MDCO) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. The Medicines earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.4256828514031 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:

The Medicines (NASDAQ:MDCO) opened at $26.21 on Friday. The Medicines has a 52 week low of $25.40 and a 52 week high of $55.95. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42.

The Medicines (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.37) by $0.95. The business had revenue of $16.87 million during the quarter, compared to the consensus estimate of $26.06 million. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The Medicines’s revenue for the quarter was down 55.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.64) earnings per share. equities research analysts anticipate that The Medicines will post -8.86 EPS for the current fiscal year.

A number of research firms have recently weighed in on MDCO. ValuEngine raised The Medicines from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Chardan Capital reissued a “buy” rating and set a $85.00 target price on shares of The Medicines in a report on Wednesday, September 20th. Guggenheim began coverage on The Medicines in a report on Monday, October 23rd. They set a “buy” rating and a $45.00 target price for the company. Citigroup raised The Medicines from a “sell” rating to an “outperform” rating in a report on Thursday, November 30th. Finally, Jefferies Group reissued a “buy” rating and set a $54.00 target price on shares of The Medicines in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $53.67.

In related news, Director Alexander J. Denner purchased 170,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average price of $30.03 per share, with a total value of $5,105,100.00. Following the completion of the purchase, the director now directly owns 6,663 shares in the company, valued at $200,089.89. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.22% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “The Medicines (MDCO) Earning Somewhat Positive Press Coverage, Analysis Finds” was first published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2017/12/10/the-medicines-mdco-earning-somewhat-positive-press-coverage-analysis-finds.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Insider Buying and Selling by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply